Hepatocellular Cancer Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Cancer, Hepatocellular

IndicationStatusPhase
DBCOND0037277 (Hepatocellular Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03572582Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular CarcinomaTreatment